✦ LIBER ✦

Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial

✍ Scribed by Garassino, Marina Chiara; Martelli, Olga; Broggini, Massimo; Farina, Gabriella; Veronese, Silvio; Rulli, Eliana; Bianchi, Filippo; Bettini, Anna; Longo, Flavia; Moscetti, Luca; Tomirotti, Maurizio; Marabese, Mirko; Ganzinelli, Monica; Lauricella, Calogero; Labianca, Roberto; Floriani, Irene; Giaccone, Giuseppe; Torri, Valter; Scanni, Alberto; Marsoni, Silvia

Book ID: 120612265
Publisher: The Lancet
Year: 2013
Tongue: English
Weight: 279 KB
Volume: 14
Category: Article
ISSN: 1470-2045
DOI: 10.1016/S1470-2045(13)70310-3

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Randomized Phase III Trial of Erlotinib

Randomized Phase III Trial of Erlotinib Versus Docetaxel As Second- or Third-Line Therapy in Patients With Advanced Non-Small-Cell Lung Cancer: Docetaxel and Erlotinib Lung Cancer Trial (DELTA)

✍ Kawaguchi, T.; Ando, M.; Asami, K.; Okano, Y.; Fukuda, M.; Nakagawa, H.; Ibata, 📂 Article 📅 2014 🏛 American Society of Clinical Oncology 🌐 English ⚖ 183 KB

A phase II trial of erlotinib in patient

A phase II trial of erlotinib in patients with EGFR wild-type advanced non-small-cell lung cancer

✍ Takashi Kobayashi; Tomonobu Koizumi; Toshihide Agatsuma; Masanori Yasuo; Kenji T 📂 Article 📅 2012 🏛 Springer 🌐 English ⚖ 271 KB

Vandetanib plus docetaxel versus docetax

Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial

✍ Roy S Herbst; Yan Sun; Wilfried EE Eberhardt; Paul Germonpré; Nagahiro Saijo; Ca 📂 Article 📅 2010 🏛 The Lancet 🌐 English ⚖ 327 KB

A randomized phase 2 trial of erlotinib

A randomized phase 2 trial of erlotinib versus pemetrexed as second-line therapy in the treatment of patients with advanced EGFR wild-type and EGFR FISH-positive lung adenocarcinoma

✍ Li, Ning; Ou, Wei; Yang, Hua; Liu, Qian-Wen; Zhang, Song-Liang; Wang, Bao-Xiao; 📂 Article 📅 2014 🏛 John Wiley and Sons 🌐 English ⚖ 229 KB

Erlotinib versus standard chemotherapy a

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

✍ Rafael Rosell; Enric Carcereny; Radj Gervais; Alain Vergnenegre; Bartomeu Massut 📂 Article 📅 2012 🏛 The Lancet 🌐 English ⚖ 246 KB

Docetaxel versus docetaxel plus gemcitab

Docetaxel versus docetaxel plus gemcitabine as front-line treatment of patients with advanced non-small cell lung cancer: A randomized, multicenter phase III trial

✍ Georgoulias, Vassilis; Androulakis, Nikolaos; Kotsakis, Athanasios; Hatzidaki, D 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 239 KB